#1 Clinical Trials Search in Europe

Sunitinib

Sunitinib, also known as SU011248 or Sutent, is a promising drug being studied in various clinical trials for its potential in treating different types of cancer. This article explores the use of Sunitinib in clinical trials, focusing on its applications in metastatic breast cancer, non-small cell lung cancer, Von Hippel-Lindau syndrome, melanoma, and prostate cancer. We’ll examine how this drug works, its potential benefits, and the ongoing research to determine its effectiveness and safety in cancer treatment.

Table of Contents

What is Sunitinib?

Sunitinib is a medication used in the treatment of various types of cancer. It’s also known by its brand name Sutent and other names such as SU011248, SU010398, PHA-290940AD, and SUNITINIB L-Malate salt[1][2]. Sunitinib belongs to a class of drugs called multi-targeted receptor tyrosine kinase inhibitors. This means it works by blocking several proteins in cancer cells that help them grow and divide[3].

How Sunitinib Works

Sunitinib is a multi-target inhibitor, which means it affects multiple processes in cancer cells. Specifically, it targets proteins called VEGFR1-3, PDGFR-α/β, FLT3, c-KIT, RET, and CSF-1R[4]. By blocking these proteins, Sunitinib can:

  • Stop the growth of blood vessels that feed tumors (a process called angiogenesis)
  • Slow down or stop the growth of cancer cells
  • Potentially cause cancer cells to die

This multi-targeted approach makes Sunitinib effective against various types of cancer that rely on these proteins for growth and survival[4].

Conditions Treated with Sunitinib

Sunitinib has been studied and used in the treatment of several types of cancer, including:

  • Renal Cell Carcinoma (RCC): This is a type of kidney cancer. Sunitinib is approved as a first-line treatment for advanced or metastatic RCC[5][6].
  • Gastrointestinal Stromal Tumors (GIST): Sunitinib is used in patients with GIST that has not responded to or cannot be treated with surgery or another medication called imatinib[1].
  • Pancreatic Neuroendocrine Tumors: While not mentioned in the provided trials, Sunitinib is also approved for treating certain types of pancreatic cancer.
  • Other Cancers: Research is ongoing to evaluate Sunitinib’s effectiveness in other types of cancer, such as ovarian cancer and glioblastoma (a type of brain tumor)[3][4].

Dosage and Administration

Sunitinib is taken orally in the form of capsules. The typical dosing schedules include:

  • Standard Schedule: 50 mg once daily for 4 weeks, followed by a 2-week break (6-week cycle)[5].
  • Continuous Daily Dosing: Some studies have explored a continuous dosing of 37.5 mg daily without breaks[6].

The dosage may be adjusted based on how well a patient tolerates the medication. It’s important to take Sunitinib exactly as prescribed by your doctor[5][6].

Effectiveness of Sunitinib

Clinical trials have shown Sunitinib to be effective in treating various cancers:

  • Renal Cell Carcinoma: Sunitinib has demonstrated improved progression-free survival (the time during which the cancer does not grow) and overall survival in patients with advanced RCC[5][6].
  • Gastrointestinal Stromal Tumors: In patients with GIST that no longer responds to imatinib, Sunitinib has shown to delay tumor growth[1].
  • Other Cancers: Research is ongoing to determine Sunitinib’s effectiveness in other types of cancer[3][4].

The effectiveness of Sunitinib can vary from person to person and may depend on factors such as the type and stage of cancer, overall health, and previous treatments[5][6][1].

Side Effects and Safety

Like all medications, Sunitinib can cause side effects. Common side effects reported in clinical trials include:

  • Fatigue
  • Diarrhea
  • Nausea
  • Loss of appetite
  • Changes in skin or hair color
  • Hand-foot syndrome (redness, pain, and swelling of hands and feet)
  • High blood pressure
  • Mouth sores
  • Weakness
  • Changes in blood cell counts

More serious side effects can occur, although they are less common. These may include liver problems, heart problems, or severe skin reactions. It’s crucial to report any side effects to your healthcare provider promptly[7].

Quality of Life Considerations

While Sunitinib can be effective in treating cancer, it’s important to consider how it might affect your overall quality of life. Some studies have used questionnaires to assess patients’ experiences with Sunitinib:

  • FACIT-Fatigue Scale: This measures fatigue levels in patients with chronic illnesses[6].
  • FACT-Kidney Symptom Index (FKSI): This assesses symptoms specific to kidney cancer patients[6].
  • FKSI-19: This expanded version looks at disease-related symptoms, treatment side effects, and overall well-being[7].

These assessments help doctors understand how Sunitinib affects patients beyond just treating the cancer. They can use this information to adjust treatment plans and provide better supportive care[6][7].

Cancer Type Trial Phase Dosage Key Objectives
Metastatic Breast Cancer Phase II 50 mg daily, 4 weeks on, 2 weeks off Evaluate efficacy as consolidation therapy after taxane chemotherapy
Non-Small Cell Lung Cancer Phase II 37.5 mg daily for 42 days per cycle Assess disease control rate in elderly patients (>70 years)
Von Hippel-Lindau Syndrome Phase II 50 mg daily, 4 weeks on, 2 weeks off Evaluate safety and efficacy in VHL patients
Melanoma Phase I/II Varied (in combination with Temozolomide) Determine safety and appropriate dose in combination therapy
Prostate Cancer Phase I 37.5 mg or 50 mg daily for 1-4 weeks Evaluate effects on prostate tumors and determine maximum tolerable dose

FAQ

  • What is Sunitinib and how does it work? Sunitinib (also known as SU011248 or Sutent) is a multi-targeted receptor tyrosine kinase inhibitor. It works by blocking several proteins that help cancer cells grow and spread, including vascular endothelial growth factor receptors (VEGFR) and platelet-derived growth factor receptors (PDGFR). By inhibiting these proteins, Sunitinib may help slow down or stop the growth of cancer cells.
  • What types of cancer is Sunitinib being studied for? Based on the clinical trials data provided, Sunitinib is being studied for various types of cancer, including metastatic breast cancer, non-small cell lung cancer, Von Hippel-Lindau syndrome, melanoma, and prostate cancer. Researchers are exploring its potential effectiveness in these different cancer types.
  • How is Sunitinib administered in clinical trials? In the clinical trials mentioned, Sunitinib is typically administered orally. The dosage and schedule vary depending on the specific trial and cancer type. For example, in some trials, it's given at 50 mg daily for 4 weeks followed by 2 weeks off, while in others, it's given at 37.5 mg daily for different durations.
  • What are some potential benefits of Sunitinib in cancer treatment? Potential benefits of Sunitinib include its ability to target multiple cancer growth pathways, potentially slowing down or stopping cancer progression. In some trials, researchers are studying if it can shrink tumors, delay tumor progression, or improve progression-free survival. It's also being explored as a consolidation therapy after other treatments and in combination with other drugs.
  • Are there any side effects associated with Sunitinib? While specific side effects aren't detailed in the provided data, clinical trials often include safety evaluations. In general, targeted therapies like Sunitinib can have side effects, which is why researchers are carefully studying different doses and schedules to determine the maximum tolerable dose. It's important for patients to discuss potential side effects with their healthcare providers.

Ongoing Clinical Trials on Sunitinib

  • Study of Lutetium (177Lu) Oxodotreotide for Patients with Recurrent Meningioma Without Surgery or Radiotherapy Options

    Recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Austria Denmark France Germany Italy The Netherlands +2

  • Study on RYZ101 for Patients with Advanced Gastroenteropancreatic Neuroendocrine Tumors After Previous Treatment

    Recruiting

    1 1 1 1
    Investigated drugs:
    Belgium France The Netherlands Spain

  • Study on the Effectiveness of Entrectinib and Other Drug Combinations for Patients with Advanced Solid Tumors, Multiple Myeloma, or Non-Hodgkin Lymphoma

    Recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    The Netherlands

  • Study on Long-term Safety of Nivolumab and Drug Combination for Cancer Patients from Previous BMS Trials

    Recruiting

    1 1 1
    Investigated drugs:
    Austria Belgium Czechia France Germany Greece +4

  • Study on Continuing Somatostatin Analogues with Sunitinib, Octreotide, and Lutetium (177Lu) Oxodotreotide for Patients with Neuroendocrine Tumors

    Recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium The Netherlands

  • Study comparing XL092 plus nivolumab versus sunitinib for patients with advanced or metastatic non-clear cell kidney cancer

    Not yet recruiting

    1 1 1 1
    Investigated drugs:
    Bulgaria Croatia Czechia Denmark Finland France +8

  • Study on Sunitinib and Nivolumab with Chemotherapy for Patients with Advanced Soft Tissue and Bone Sarcomas

    Not recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Italy Spain

  • Study Comparing Ripretinib and Sunitinib for Patients with Advanced Gastrointestinal Stromal Tumors Previously Treated with Imatinib

    Not recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    France Italy The Netherlands Norway Spain

  • Study of Dabrafenib and Drug Combination for Patients with Metastatic Non-Clear Cell Kidney Cancer

    Not recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Denmark

  • Study Comparing Nivolumab and Cabozantinib with Sunitinib for Patients with Untreated Advanced Kidney Cancer

    Not recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Czechia Germany Greece Italy Poland Romania +1

Glossary

  • Sunitinib: A multi-targeted receptor tyrosine kinase inhibitor used in cancer treatment. It's also known as SU011248 or Sutent.
  • Metastatic Breast Cancer: Breast cancer that has spread beyond the breast to other parts of the body.
  • Non-Small Cell Lung Cancer (NSCLC): A type of lung cancer that is the most common form of lung cancer.
  • Von Hippel-Lindau Syndrome (VHL): A rare genetic disorder characterized by the formation of tumors and cysts in various parts of the body.
  • Melanoma: A type of skin cancer that develops from the pigment-producing cells known as melanocytes.
  • Prostate Cancer: A type of cancer that occurs in the prostate gland in males.
  • Radical Prostatectomy: A surgical procedure to remove the entire prostate gland and surrounding tissues.
  • Progression-Free Survival (PFS): The length of time during and after treatment that a patient lives with the disease but it does not get worse.
  • VEGF/PDGF: Vascular Endothelial Growth Factor and Platelet-Derived Growth Factor, proteins involved in the growth of blood vessels that support tumor growth.
  • Tyrosine Kinase Inhibitor: A type of targeted therapy that blocks specific enzymes called tyrosine kinases, which are involved in cancer cell growth and survival.
  • Consolidation Therapy: Treatment given after initial therapy to prolong the duration of response or remission.
  • Maximum Tolerable Dose (MTD): The highest dose of a drug that does not cause unacceptable side effects.

References

  1. https://clinicaltrials.gov/study/NCT00716820
  2. https://clinicaltrials.gov/study/NCT00459979
  3. https://clinicaltrials.gov/study/NCT00543049
  4. https://clinicaltrials.gov/study/NCT00535379
  5. https://clinicaltrials.gov/study/NCT00254540
  6. https://clinicaltrials.gov/study/NCT00338884
  7. https://clinicaltrials.gov/study/NCT03140176